Table 6.

Subgroup analysis of CIMT abnormalities adjusting for age among different groups by cfPWV and CBP.

	Variance	β	SE	Exp β	95% CI	P value
Model 1	Antihypertensive drugs (yes or no)	1.340	0.262	3.817	2.285–6.377	<0.001
Model 2	Age (≥60 years)	1.345	0.301	3.836	2.125–6.925	<0.001
	Antihypertensive drugs (yes or no)	1.317	0.273	3.731	2.186–6.366	<0.001
Model 3	Age (≥60 years)	1.319	0.306	3.739	2.054–6.808	<0.001
	Antihypertensive drugs (yes or no)	1.121	0.282	3.068	1.764–5.336	<0.001
	Lipid-lowering drugs (yes or no)	0.726	0.265	2.066	1.229–3.474	0.006
Model 4	Age (≥60 years)	1.161	0.327	3.192	1.682–6.058	<0.001
	Antihypertensive drugs (yes or no)	1.309	0.302	3.703	2.048–6.693	<0.001
	Lipid-lowering drugs (yes or no)	0.671	0.272	1.956	1.149–3.330	0.013
	Group (control) (Ref)					0.043
	Group (cfPWV/CBP)	−0.163	0.504	0.850	0.317–2.281	0.747
	Group (cfPWV)	2.008	1.117	7.447	0.835–66.442	0.072
	Group (CBP)	−0.763	0.358	0.466	0.231–0.941	0.033

Model 1 adjusted for sex (male or female), height, BMI, body mass index, smoking history, heart rate, peripheral mean arterial pressure (p-MAP), glucose-lowering drugs (yes or no), and antihypertensive drugs (yes or no).

Model 2 adjusted for sex, height, BMI, smoking history, heart rate, p-MAP, glucose-lowering drugs (yes or no), antihypertensive drugs (yes or no), and age.

Model 3 adjusted for sex, height, BMI, smoking history, heart rate, p-MAP, glucose-lowering drugs (yes or no), antihypertensive drugs (yes or no), age, and lipid-lowering drugs (yes or no).

Model 4 adjusted for sex, height, BMI, smoking history, heart rate, p-MAP, glucose-lowering drugs (yes or no), antihypertensive drugs (yes or no), age, lipid-lowering drugs (yes or no), and groups.

The bold values represent the values that are statistically significant (P < 0.05).